Compounds > 2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione
Page last updated: 2024-11-13
2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione
Description
The compound you described, 2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione, is a complex organic molecule. It's quite likely this compound is a **potential drug candidate** due to its structural features and the research areas it likely belongs to:
* **Quinazoline core:** The presence of a quinazoline ring is common in pharmaceutical compounds. Quinazolines are known to possess diverse biological activities, including anti-inflammatory, anti-cancer, and anti-microbial properties.
* **Isoindoline-1,3-dione (phthalimide) moiety:** The phthalimide group is also frequently found in drugs. It contributes to various properties, including stability, bioactivity, and potential for conjugation with other molecules.
* **Substituents:** The specific substituents (methyl, fluoroethoxy, isopropoxy) on the quinazoline and phthalimide rings are likely chosen to fine-tune the compound's properties, such as solubility, binding affinity to specific targets, and overall pharmacokinetic profile.
**Potential research areas:**
* **Cancer treatment:** The complex structure and presence of the quinazoline ring suggest potential anti-cancer activity. Quinazoline derivatives have been investigated for their ability to target various signaling pathways involved in tumor growth and proliferation.
* **Anti-inflammatory therapies:** The phthalimide moiety might contribute to anti-inflammatory properties, which could be valuable in treating inflammatory diseases.
* **Other therapeutic applications:** The specific arrangement of functional groups could lead to activity against other disease targets, such as bacterial infections, viral infections, or neurological disorders.
**Importance for research:**
This complex compound is likely of interest to researchers in medicinal chemistry and drug discovery. It represents a potential lead compound with a unique structure that could exhibit promising biological activity. Researchers would aim to:
* **Synthesize and characterize the compound.**
* **Evaluate its pharmacological activity in laboratory settings.**
* **Determine its mechanism of action.**
* **Investigate its pharmacokinetic properties (absorption, distribution, metabolism, and excretion).**
* **Conduct further research to optimize its potency, selectivity, and safety profile for potential therapeutic use.**
**Disclaimer:** I am an AI chatbot and cannot provide medical or research advice. The information provided above is based on common structural features of pharmaceutical compounds and is not a guarantee of the specific properties or research applications of the mentioned compound.
To learn more about this specific compound, you would need to consult relevant scientific literature and databases that focus on drug discovery and development.
2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione: a phosphodiesterase 10A radioligand; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
PubMed CID | 76462590 |
MeSH ID | M000607655 |
Synonyms (4)
Synonym |
8W81O23W8A |
mni-659 |
2-(2-(3-(4-(2-fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione |
Q27271113 |
Research
Studies (6)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 6 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.56
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 12.56 (24.57) | Research Supply Index | 1.95 (2.92) | Research Growth Index | 4.51 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |